Indication
Increntin Effect
1 clinical trial
3 products
Clinical trial
The Effect of Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1) and Glucagon-like Peptide-2 (GLP-2) in Individuals With Genetically Altered Receptor FunctionStatus: Recruiting, Estimated PCD: 2027-12-01
Product
GIP(1-42)Product
GLP-1Product
GLP-2